BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 11249827)

  • 1. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model.
    Lister PD
    Clin Infect Dis; 2001 Mar; 32 Suppl 1():S33-8. PubMed ID: 11249827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
    Odenholt I; Cars O
    J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Streptococcus pneumoniae response to repeated moxifloxacin or levofloxacin exposure in a rabbit tissue cage model.
    Xuan D; Zhong M; Mattoes H; Bui KQ; McNabb J; Nicolau DP; Quintiliani R; Nightingale CH
    Antimicrob Agents Chemother; 2001 Mar; 45(3):794-9. PubMed ID: 11181363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
    Lister PD; Sanders CC
    J Antimicrob Chemother; 2001 Jun; 47(6):811-8. PubMed ID: 11389113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
    Deryke CA; Du X; Nicolau DP
    J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AUC(0-t)/MIC is a continuous index of fluoroquinolone exposure and predictive of antibacterial response for Streptococcus pneumoniae in an in vitro infection model.
    Zelenitsky SA; Ariano RE; Iacovides H; Sun S; Harding GK
    J Antimicrob Chemother; 2003 Apr; 51(4):905-11. PubMed ID: 12654762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
    Schafer J; Hovde LB; Simonson D; Rotschafer JC
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics of moxifloxacin and levofloxacin simulating human serum and lung concentrations.
    Schubert S; Dalhoff A; Stass H; Ullmann U
    Infection; 2005 Dec; 33 Suppl 2():15-21. PubMed ID: 16518707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
    Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
    Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.
    Firsov AA; Vostrov SN; Lubenko IY; Arzamastsev AP; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2004 Jul; 54(1):178-86. PubMed ID: 15190041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the bactericidal activity of moxifloxacin and levofloxacin against Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Klebsiella pneumoniae.
    Lemmen SW; Häfner H; Klik S; Lütticken R; Zolldann D
    Chemotherapy; 2003 May; 49(1-2):33-5. PubMed ID: 12714807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro activity of linezolid, moxifloxacin, levofloxacin, clindamycin and rifampin, alone and in combination, against Staphylococcus aureus and Staphylococcus epidermidis].
    Soriano A; Jurado A; Marco F; Almela M; Ortega M; Mensa J
    Rev Esp Quimioter; 2005 Jun; 18(2):168-72. PubMed ID: 16130039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
    D'Arienzo PA; Wagner RS; Jamison T; Bell B; Dajcs JJ; Stroman DW
    Adv Ther; 2010 Jan; 27(1):39-47. PubMed ID: 20174904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic predictors of antimicrobial efficacy: moxifloxacin and Streptococcus pneumoniae.
    Schentag JJ
    J Chemother; 2002 Feb; 14 Suppl 2():13-21. PubMed ID: 12003136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
    Cafini F; Alou L; Sevillano D; Valero E; Prieto J;
    Int J Antimicrob Agents; 2004 Oct; 24(4):334-8. PubMed ID: 15380257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses.
    Firsov AA; Lubenko IY; Vostrov SN; Kononenko OV; Zinner SH; Portnoy YA
    J Antimicrob Chemother; 2000 Nov; 46(5):725-32. PubMed ID: 11062191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
    Kim SY; Lim JA; Choi JS; Choi EC; Joo CK
    Cornea; 2007 Jul; 26(6):720-5. PubMed ID: 17592324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC; Novosad BD; Ramadan RT; Wiskur B; Moyer AL
    Adv Ther; 2009 Apr; 26(4):447-54. PubMed ID: 19381523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.